Sign In
Buy TEM
$50.56
-1.76 (-3.36%)
At Close: Jun 16, 2026
Tempus Shares Jump After Strong Preliminary 2025 Results
01:35pm, Monday, 12'th Jan 2026
Tempus AI (TEM) shares rose about 10% on Monday after the company filed preliminary, unaudited results showing roughly $1.27 billion in 2025 revenue.The filing
Tempus AI's Pharma Momentum Accelerates
01:08pm, Monday, 12'th Jan 2026
Tempus AI (TEM) is starting 2026 with clear momentum as demand from drugmakers for AI powered tools continues to accelerate. The healthcare AI company said prel
Tempus AI Stock Rallies 105% in a Year: Should Investors Still Hold?
08:56am, Monday, 12'th Jan 2026
TEM has surged 105% in a year on AI-driven growth, FDA clearances and improving margins, but GAAP losses still cloud the outlook.
Tempus and NYU Langone Health Announce Strategic Collaboration to Advance Precision Oncology
08:30am, Monday, 12'th Jan 2026
CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, and NYU Langone Health, one of the nation's premier academic medical centers, today announced a multi-year
Northwestern Medicine Selects Tempus to Expand Genomic Testing
07:00am, Monday, 12'th Jan 2026
CHICAGO--(BUSINESS WIRE)--Northwestern Medicine and Tempus AI, Inc. (NASDAQ: TEM) are collaborating to expand access to genomic testing for Northwestern Medicine cancer patients. The goal is to provid
Tempus AI Stock Soars After Posting Triple-Digit Diagnostics Growth
05:47am, Monday, 12'th Jan 2026
Tempus AI (NASDAQ: TEM) stock rose after releasing preliminary Q4 and 2025 results, with revenue of $1.27B in 2025 and $367M in Q4.
Stock Market Today: Dow Jones, S&P 500 Futures Tumble As DOJ Serves Federal Reserve—Vistra, Tempus AI, Alibaba In Focus
05:33am, Monday, 12'th Jan 2026
U.S. stock futures declined on Monday after a positive close on Friday. Futures of major benchmark indices were trading lower.
Tempus Achieves Record Total Contract Value Exceeding $1.1 Billion
05:30pm, Sunday, 11'th Jan 2026
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a record Total Contract Value (TCV) of >$1.1 bil
Tempus Announces Preliminary Fourth Quarter and Full Year 2025 Results
05:00pm, Sunday, 11'th Jan 2026
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced select, preliminary, unaudited results for the f
Tempus AI Stock Surges 82.4% in a Year: What's Driving It?
08:46am, Friday, 09'th Jan 2026
TEM shares are up 82.4% in a year as Genomics revenues surge, Data & Services scale, FDA clearances and EBITDA turns positive.
Inverse Cramer Wins Again: Opposite Picks Of Investor Beat Nancy Pelosi In 2025
06:18pm, Thursday, 08'th Jan 2026
In the battle of investing the opposite of what Jim Cramer says versus investing in Nancy Pelosi's stock picks, here's who won in 2025.
Tempus Announces Eight Abstracts Accepted for Presentation at the 2026 ASCO® Gastrointestinal Cancers Symposium
08:30am, Thursday, 08'th Jan 2026
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that eight abstracts have been accepted for pres
Rune Labs Taps Tempus Exec as New CEO to Expand AI-Enabled Neurology Care
08:15am, Thursday, 08'th Jan 2026
SAN FRANCISCO--(BUSINESS WIRE)--Rune Labs, the leader in precision medicine for neurology, today announced Amy Gordon Franzen as its new Chief Executive Officer. Amy will lead the company's next stage
TEM's Stable Solvency and Financial Strength Are Gaining Attention
08:36am, Wednesday, 07'th Jan 2026
Tempus AI posts a strong Q3 2025 balance sheet with $760M cash, no current debt, and positive adjusted EBITDA, boosting flexibility and solvency.
Tempus to Present at 44th Annual J.P. Morgan Healthcare Conference
08:30am, Tuesday, 06'th Jan 2026
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, will participate in the 44th Annual J.P. Morgan Healthcare Confe
